Disease · MONDO_0005227

abscess

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. abscess. Diseases, record MONDO_0005227. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005227

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: abscess; Open Targets
Open Targets ID: MONDO_0005227; Open Targets
Other names: abscess (disease), abscess (disorder), abscess NOS, abscess NOS (disorder), abscess morphology; Open Targets
MeSH: D000038; MeSH
NCI Thesaurus: C26686; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 10 drugs, from DailyMed; Open Targets

Drugs10

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CLINDAMYCIN PHOSPHATE	CHEMBL3184512	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
ALTEPLASE	CHEMBL1201593	Enzyme	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
FENTANYL	CHEMBL596	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
MORPHINE	CHEMBL70	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
METHYLENE BLUE	CHEMBL550495	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
TRIMETHOPRIM	CHEMBL22	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CLINDAMYCIN	CHEMBL1753	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CO-TRIMOXAZOLE	CHEMBL58061	Small molecule	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
DOXYCYCLINE	CHEMBL1200699	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SULFAMETHOXAZOLE	CHEMBL443	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets6

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
OPRM1	Mu-type opioid receptor	2	Mu opioid receptor agonist	Phase 3	https://conductscience.org/library/genes/4988	Drugs and targets
MMP1	Interstitial collagenase	1	Matrix metalloproteinase-1 inhibitor	Phase 2	https://conductscience.org/library/genes/4312	Drugs and targets
MMP13	Collagenase 3	1	Matrix metalloproteinase 13 inhibitor	Phase 2	https://conductscience.org/library/genes/4322	Drugs and targets
MMP7	Matrilysin	1	Matrix metalloproteinase 7 inhibitor	Phase 2	https://conductscience.org/library/genes/4316	Drugs and targets
MMP8	Neutrophil collagenase	1	Matrix metalloproteinase 8 inhibitor	Phase 2	https://conductscience.org/library/genes/4317	Drugs and targets
PLAT	Tissue-type plasminogen activator	1	Tissue-type plasminogen activator exogenous protein	Phase 3	https://conductscience.org/library/genes/5327	Drugs and targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00730028	Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus	Phase 2	1,310	2016-03-17	Staphylococcal Infection	CLINDAMYCIN, SULFAMETHOXAZOLE, TRIMETHOPRIM	Its record names the disease	ClinicalTrials.gov
NCT01549002	Efficacy of Intranasal Fentanyl at Reducing Pain During Abscess Incision and Drainage (I&D) in Children	Phase 3	20	2015-08-21	Abscess, Pain	FENTANYL, MORPHINE	Its record names the disease	ClinicalTrials.gov
NCT03637400	Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment	Phase 2	269		Methicillin-resistant Staphylococcus Aureus, Skin Infection	DOXYCYCLINE, TRIMETHOPRIM	Its record names the disease	ClinicalTrials.gov
NCT06052956	Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses	Phase 2	120		Abscess	METHYLENE BLUE	Its record names the disease	ClinicalTrials.gov
NCT01576679	Safety and Efficacy of the Use of Tissue Plasminogen Activator (tPA) in Intra-Abdominal Collections in Children - A Prospective Study	Phase 3	28		Intra-abdominal Abscess	ALTEPLASE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02240498	Safety and Feasibility Study of Methylene Blue Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities	Phase 1	21		Abscess	METHYLENE BLUE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Intranasal Fentanyl vs Intravenous Morphine: Number of Patients Satisfied With Analgesia Administered	10 of 10	4 of 10	20	NCT01549002	Trial comparisons
Intranasal Fentanyl vs Intravenous Morphine: serious adverse events	0 of 10	1 of 10	20	NCT01549002	Trial comparisons

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
27387971	RESULT	1	PubMed
25785967	RESULT	1	PubMed
38501946	DERIVED	1	PubMed
38414658	DERIVED	1	PubMed
38316055	DERIVED	1	PubMed
37961683	DERIVED	1	PubMed
37464107	DERIVED	1	PubMed
28657870	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005227

GET https://conductscience.org/api/diseases/v1/MONDO_0005227/drugs

API reference For AI assistants